Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...

One of the drugs mentioned in the report is xanomeline/tropsium chloride (Cobenfy; Karuna Therapeutics, acquired by Bristol Myers Squibb), used to treat patients with schizophrenia and psychosis ...

In September 2024, the Food and Drug Administration (FDA) approved Cobenfy, a drug to treat schizophrenia that analysts believe could generate a whopping $7.5 billion in revenue at its peak.

The US regulator has cleared the combination of muscarinic M1 and M4 agonist xanomeline tartrate and muscarinic antagonist trospium chloride – formerly known as KarXT – under the Cobenfy brand ...

Pokemon TCG fans celebrate the wholesome moment when a fan's daughter opens a rare God Pack. God Pack cards are all special in type and usually worth a fair bit of money, including holographic ...

Windows 11 has a simplified Start menu that replaces Live Tiles with a more traditional app launcher and removes many legacy features. However, the Settings app still offers plenty of ...

That’s why it’s best to start as soon as possible and think long-term. Investing in the stock for 20 years could grow the pot to £100,000. Shifting that much capital into a portfolio of high ...